EU: Innovative Medicines Initiative 2 (IMI2) - 15. Call
30/07/18 14:55
This call is open to submit project applications in following topics:
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic Read More…
• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic Read More…
GLIOMARK1 clinical study successfully completed
17/05/18 10:55
The GLIOMARK consortium is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed. Read More…